您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Rilmenidine-d4
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Rilmenidine-d4
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Rilmenidine-d4图片
CAS NO:85047-14-9
包装与价格:
包装价格(元)
500 μg电议
1mg电议

产品介绍
An internal standard for the quantification of rilmenidine
Cas No.85047-14-9
Canonical SMILES[2H]C(C([2H])([2H])O1)([2H])N=C1NC(C2CC2)C3CC3
分子式C10H12D4N2O
分子量184.3
溶解度DMF: Soluble,DMSO: Soluble,Methanol: Soluble
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Rilmenidine-d4is intended for use as an internal standard for the quantification of rilmenidine by GC- or LC-MS. Rilmenidine is an antihypertensive agent.1It binds to imidazole receptors in bovine rostral ventrolateral medulla homogenates (Ki= 6.1 nM), as well as α2-adrenergic receptors in bovine prefrontal cortex homogenates (Ki= 87 nM). Rilmenidine induces hypotension and bradycardia in anesthetized rats (ED50s = 0.25 and 0.35 mg/kg, respectively). It also reduces mean arterial pressure and renal sympathetic nerve activity in a rabbit model of renal hypertension induced by a renal artery clip when administered at a dose of 2.5 mg/kg.2Rilmenidine (1 µM) increases levels of LC3-II, a marker of autophagy, in PC12 cells.3Formulations containing rilmenidine have been used in the treatment of hypertension.

1.Gomez, R.E., Ernsbarger, P., Feinland, G., et al.Rilmenidine lowers arterial pressure via imidazole receptors in brainstem C1 areaEur. J. Pharmacol.195(2)181-191(1991) 2.Burke, S.L., Evans, R.G., and Head, G.A.Effects of chronic sympatho-inhibition on renal excretory function in renovascular hypertensionJ. Hypertens.29(5)945-952(2011) 3.Williams, A., Sarkar, S., Cuddon, P., et al.Novel targets for Huntington's disease in an mTOR-independent autophagy pathwayNat. Chem. Biol.4(5)295-305(2008)